A director at Catalyst Pharmaceuticals Inc sold 200,000 shares at 26.087USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Steelcase to Webcast First Quarter Fiscal 2026 Conference Call GRAND RAPIDS, Mich., June 05, 2025 (GLOBE NEWSWIRE) -- Steelcase Inc. (NYSE: SCS) will webcast a discussion of its first quarter fiscal year 2026 financial results on Thursday, June 26, 2025 at 8:30 a.m. ET. A link to the webcast will be available at and a replay of the webcast will be available shortly after the call concludes. The news release detailing the financial results will be issued the previous day, June 25, 2025, after the market closes. Steelcase Inc. will hold its Annual Meeting of Shareholders on Wednesday, Ju...
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company’s President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company’s executive leadership team. He succeeds Dr...
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Confer...
Q3 2025 Results: Lesaka delivers on guidance, reaffirms FY2025 outlook and projects positive net income in FY2026 JOHANNESBURG, May 07, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the third quarter of fiscal 2025 (“Q3 2025”). Q3 2025 performance: Revenue of $135.7 million (ZAR 2.5 billion) was at the midpoint of our Revenue guidance and compares to $138.2 million (ZAR 2.6 billion) in Q3 2024.Net Revenue (a non-GAAP measure) of $73.4 million (ZAR 1.4 billion) was at the midpoint of our Net Revenue guidance increasing 43% ...
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conferenc...
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday,...
Lesaka to Host Webcast to Review Third Quarter 2025 Results JOHANNESBURG, April 08, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka" or the "Company") today announced it will release third quarter 2025 results after the U.S. market close on May 7, 2025. Lesaka management will host a presentation webcast on May 8, 2025, on at 8:00am EDT (2:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the webcast will be able to submit questions during the...
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the Ne...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.